[New Publication] Parabacteroides goldsteinii: A Next-Generation Probiotic Targeting the Gut–Brain Axis in Parkinsonism

We are proud to announce that the ReviveBio Scientific Team, in collaboration with leading academic and medical research institutes, has published new peer-reviewed research in the Journal of Advanced Research. This study demonstrates that Parabacteroides goldsteinii, when administered at the prodromal stage, significantly mitigates Parkinson’s-like neurodegeneration in LRRK2 G2019S mutant mice. The neuroprotective effects are mediated through:

• Suppression of gut-driven TLR4-dependent inflammation
• Restoration of intestinal barrier integrity and mitochondrial function
• Reduction of microglial activation and α-synuclein aggregation in the brain
• Activation of a non-canonical IL-12 receptor–dependent neurotrophic pathway, without triggering classical STAT4 inflammatory signaling

This research underscores how next-generation probiotics may reshape our understanding of gut–brain communication in parkinsonism—shifting the focus from symptomatic management to upstream biological modulation.

📌 At REVIVEBIO, we are committed to advancing longevity and healthy aging through rigorous microbiome research and responsible innovation—transforming next-generation probiotics into science-driven anti-aging solutions for the future of health.